Optibrium expands UK head office with new facilities on Cambridge Innovation Park
Investment in new headquarters forms part of ongoing company growth plans.
The new facility supports the continued success of Optibrium’s drug discovery technologies and accommodates an expanding team.
CAMBRIDGE, UK, 8 June 2022 – Optibrium™, a developer of software for drug discovery, today announced the expansion of its UK headquarters with a move to larger office premises on Cambridge Innovation Park North. The new facilities accommodate Optibrium’s accelerated growth and ongoing recruitment efforts to support the continued success and development of the company’s best-in-class, innovative technology focused on improving the efficiency and productivity of the drug discovery process.
Optibrium’s new headquarters, located in one of the UK’s leading technology hubs, provide new offices, meeting rooms, social areas and on-site leisure activities to promote employee well-being. The premises will facilitate recruitment opportunities created by the company’s ongoing expansion and commercial development, such as for C++ Software Engineers, DevOps Engineers and Researchers.
Over 170 organisations worldwide, including leading pharmaceutical companies, deploy Optibrium’s computational drug discovery technology in their research programs. Its lead product, StarDrop™, is a comprehensive suite of integrated software for small molecule design, optimisation, and data analysis that enhances the speed and productivity of the drug discovery process. Cerella™, Optibrium’s proven artificial intelligence platform, empowers project teams with valuable insights from complex drug discovery data to maximise the success of preclinical discovery projects.
Headquartered in Cambridge, UK, Optibrium also has offices in Boston and San Francisco, USA.
Optibrium’s CEO Matt Segall said: “The space will enable us to accommodate new employees and provide the exciting opportunity to accelerate our growth plans. We look forward to welcoming new, highly talented software specialists and scientists dedicated to delivering our best-in-class in silico technologies and Artificial Intelligence platforms.”